Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

China Pharma Holdings (CPHI) EBITDA Margin (2016 - 2025)

China Pharma Holdings filings provide 16 years of EBITDA Margin readings, the most recent being 85.18% for Q4 2025.

  • On a quarterly basis, EBITDA Margin rose 4070.0% to 85.18% in Q4 2025 year-over-year; TTM through Dec 2025 was 70.57%, a 3694.0% increase, with the full-year FY2025 number at 70.57%, up 3694.0% from a year prior.
  • EBITDA Margin hit 85.18% in Q4 2025 for China Pharma Holdings, down from 78.57% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 13.81% in Q1 2023 to a low of 160.4% in Q2 2024.
  • Median EBITDA Margin over the past 5 years was 64.72% (2025), compared with a mean of 66.6%.
  • Biggest five-year swings in EBITDA Margin: tumbled -7441bps in 2024 and later soared 11087bps in 2025.
  • China Pharma Holdings' EBITDA Margin stood at 28.97% in 2021, then decreased by -28bps to 37.0% in 2022, then plummeted by -39bps to 51.46% in 2023, then plummeted by -145bps to 125.87% in 2024, then soared by 32bps to 85.18% in 2025.
  • The last three reported values for EBITDA Margin were 85.18% (Q4 2025), 78.57% (Q3 2025), and 49.53% (Q2 2025) per Business Quant data.